Shared blood signals link BCG vaccine protection across species

Tuberculosis remains a global health challenge, and scientists want to know why the century-old BCG vaccine protects some individuals but not others. In new work led by Douglas A. Lauffenburger, researchers looked beyond single-species studies to compare blood-based immune signals across species. Rather than relying only on human clinical trials, which can be limited by ethics and logistics, they turned to non-human primates (NHPs) vaccinated with BCG and examined which blood transcriptional patterns were associated with protection after experimental challenge. The project used a species translation modeling approach to connect animal study findings with human biology. By searching for transcriptional correlates in blood — measurable changes in gene activity profiles — the team aimed to identify immune pathways that consistently associate with protection in both NHPs and humans. This cross-species perspective is intended to reveal conserved immune mechanisms that underlie successful vaccination, offering a way to generate testable hypotheses about how BCG works when direct human evidence is scarce or unavailable.

The core methods involved profiling blood transcriptional responses and comparing challenge outcomes in BCG-vaccinated NHPs to identify pathways linked to protection. The researchers found protection-associated pathways that included both innate and adaptive immune activation mechanisms. Signaling via type I interferons and anti-mycobacterial T helper cytokines were highlighted among these pathways, pointing to coordinated early and adaptive responses as markers of effective vaccination. To see whether these associations might also apply to humans, the team partially validated their findings using publicly available microarray data collected from BCG-vaccinated infants. Those infant datasets followed children for two years, recording who developed TB and who remained healthy, allowing the investigators to test whether the same blood transcriptional signatures overlapped with protection in people. This combined animal-to-human analysis relied on species translation modeling to bridge differences between NHPs and human infants while preserving exact transcriptional signals observed in blood.

The study illustrates the promise of using animal studies strategically to illuminate human vaccine responses. By identifying blood transcriptional correlates of protection that span species — including innate and adaptive activation, type I interferon signaling, and anti-mycobacterial T helper cytokine activity — the work provides concrete hypotheses about the immune processes that matter for BCG-mediated protection. Because some human studies cannot ethically or practically reproduce the controlled challenge experiments done in NHPs, species translation modeling offers a practical route to leverage those richer animal datasets. The partial validation in human microarray data suggests that at least some of these pathways are relevant to real-world infant responses to BCG. Going forward, these cross-species signatures could help prioritize mechanistic studies, inform biomarker development, and guide the design or evaluation of improved tuberculosis vaccines by focusing attention on conserved immune processes associated with protection.